Why the study?
Reverse remodeling is the goal of chronic heart failure therapies, prompting an updated review of device-based mechanisms that biologically and physically reverse remodel the left ventricle.
Do transcatheter interventions and device-based mechanisms promote reverse left ventricular remodeling in patients with chronic heart failure?
Do transcatheter interventions and device-based mechanisms promote reverse left ventricular remodeling in patients with chronic heart failure?
This review outlines the landscape of transcatheter device therapies designed to achieve reverse left ventricular remodeling in chronic heart failure.
Reverse remodeling remains a core target in HFrEF; leaves open which interventions best achieve durable normalization.
Chronic heart failure (HF) is a clinical syndrome of myocardial dysfunction characterized by inadequate cardiac output or preserved output that can only be achieved by sustaining abnormal loading conditions. Morphologically, HF with reduced left ventricular function results in progressive chamber remodeling, meaning the ventricle dilates, operating at larger end-diastolic and end-systolic volumes, and takes on an abnormal, spherical shape that increases wall stress. Reverse remodeling is the goal of HF-directed therapies and can be achieved by biological means, ie, altering the loading conditions that, at a cellular level, promote myocardial dysfunction, or physical means, ie, directly altering myocardial mass or shape. In this review, we highlight the existing and emerging device-based mechanisms for biologically and physically reverse remodeling the left ventricle in chronic HF.
No takes yet. Share an insight, caveat, or question.
Brener et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: